Inhalable Rapamycin Aerosol Formulation for Lung Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Rapamycin's pulmonary toxicity and adverse effects, such as lung toxicity and increased cancer risk, limit its safe use for inhalation-based therapeutic delivery, making it unsuitable for treating age-related conditions and disorders via pulmonary routes.
Innovation Solution
Development of a safe and effective aerosol formulation of rapamycin that achieves high concentrations in lung tissue with minimal systemic exposure, using formulations like aqueous or dry powder compositions, to inhibit mTOR signaling with reduced toxicity, allowing for targeted delivery and prolonged therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If rapamycin is administered via inhalation for treating age-related conditions, then targeted delivery to lung tissue is achieved, but pulmonary toxicity and adverse effects occur
Solution Approach 1:
The patent changes the physical and chemical parameters of rapamycin by formulating it as an aerosol with specific particle size (0.1-10 microns) and concentration ranges (0.001-0.01% w/w). This parameter modification enables pulmonary delivery while controlling the dose to minimize toxicity, resolving the contradiction between ease of pulmonary administration and lung safety.
Solution Approach 2:
The aerosol formulation delivers rapamycin locally to the lung tissue with high concentration (achieving therapeutic levels in lung tissue while maintaining low blood levels). This localized delivery approach concentrates the drug effect at the target site while minimizing systemic exposure and associated toxicities, thereby improving the therapeutic index.
2Reliability
If rapamycin is administered systemically for anti-aging therapy, then therapeutic effect is achieved, but increased cancer risk and diabetes-like symptoms occur
Solution Approach 1:
The patent extracts the harmful systemic circulation component by using pulmonary delivery, which deposits rapamycin directly in the lungs and minimizes absorption into the bloodstream. This extraction of the drug from systemic circulation while maintaining local therapeutic effect resolves the contradiction between achieving therapeutic effect and reducing cancer risk and diabetes-like symptoms associated with systemic administration.
Solution Approach 2:
By changing the administration route from systemic (oral/IV) to pulmonary aerosol and adjusting the dose parameters (0.001-0.01% w/w in aerosol), the patent achieves therapeutic effect in lung tissue while keeping blood levels low, thereby reducing the harmful effects of cancer risk and diabetes-like symptoms.
3Power
If high concentration of rapamycin is delivered to lungs via aerosol, then biological activity is enhanced, but toxicity increases
Solution Approach 1:
The patent optimizes the concentration parameter of rapamycin in the aerosol formulation, using a specific range (0.001-0.01% w/w) that achieves sufficient biological activity in lung tissue while avoiding excessive toxicity. This precise parameter control resolves the contradiction between enhancing biological activity and minimizing toxicity.
Solution Approach 2:
The aerosol delivery system creates local high concentration of rapamycin in the lung tissue at the site of action, while the overall systemic concentration remains low. This local quality approach concentrates the therapeutic effect where needed without proportionally increasing systemic toxicity, thereby enhancing biological activity while controlling harmful effects.
Data Source
AI summary
The present invention relates to methods and compositions for anti-aging therapy and for the treatment and prophylaxis of age-related diseases and disorders in a human subject in need of such therapy or treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation, of composition comprising rapamycin, or a prodrug or derivative thereof.